1
|
Liu Y, Gao P, Liang X, Zhang Y, Yu X, Xue X, Kockaya L, Pandey P, Doerksen RJ, Wang X, Yao G, Chu W, Chen X, Song S, Hamann MT, Li L. Prenylated flavonoids with significant anti-hepatoma activity from Daphne giraldii and effects on Fibroblast Growth Factor Receptor 1 (FGFR1). Eur J Med Chem 2023; 247:115006. [PMID: 36549116 PMCID: PMC11173874 DOI: 10.1016/j.ejmech.2022.115006] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/29/2022] [Revised: 11/23/2022] [Accepted: 12/03/2022] [Indexed: 12/14/2022]
Abstract
We report here the orchestration of molecular ion networking (MoIN) and a set of computational and informatics assisted structural elucidation approaches in the discovery of 23 new prenyl-flavonoids and 13 known molecules from Daphne giraldii Nitsche (Thymelaeaceae), some of which possess significant bioactivity against hepatoma carcinoma. Daphnegiratriprenylone A (DPTP-A) represents the class of polyprenyl-flavonoids possessing a triprenyl substitution, and was identified with the guidance of mass spectrometry and nuclear magnetic resonance combined with computational approaches. This approach illustrates a paradigm shift in the application of computational tools for the direct assignment of new natural product structures and it was demonstrated to be reliable compared to conventional 2D-NMR techniques. Seventeen compounds exhibited potent and selective activity against Hep3B cells (IC50 ranging from 0.42 to 7.08 μM). Tyrosine kinase FGFR1 has emerged as a potential target of polyprenyl-flavonoids by a reverse pharmacophore mapping approach. We validated that the prenyl-flavonoids effectively inhibit FGFR1 using the Mobility Shift Assay, Western blot and molecular dynamics simulations, and the results suggest significant potency of the compounds towards FGFR1. These findings provide a new chemical class with strong links to traditional medicines, possessing reasonable safety for developing potential therapeutic agents for FGFR1-related diseases.
Collapse
Affiliation(s)
- Ying Liu
- School of Traditional Chinese Materia Medica, Shenyang Pharmaceutical University, Shenyang, 110016, PR China
| | - Pinyi Gao
- College of Pharmaceutical and Biotechnology Engineering, Shenyang University of Chemical Technology, Shenyang, 110142, PR China
| | - Xiao Liang
- College of Pharmacy, Liaoning University, 66 Chongshan Road, Shenyang, 110036, Liaoning, PR China
| | - Yangyang Zhang
- School of Traditional Chinese Materia Medica, Shenyang Pharmaceutical University, Shenyang, 110016, PR China
| | - Xiaoqi Yu
- School of Traditional Chinese Materia Medica, Shenyang Pharmaceutical University, Shenyang, 110016, PR China
| | - Xiaobian Xue
- School of Traditional Chinese Materia Medica, Shenyang Pharmaceutical University, Shenyang, 110016, PR China
| | - Lara Kockaya
- Division of Medicinal Chemistry, Department of BioMolecular Sciences, University of Mississippi, Mississippi, 38677, USA
| | - Pankaj Pandey
- National Center for Natural Products Research, School of Pharmacy, University of Mississippi, Mississippi, 38677, USA
| | - Robert J Doerksen
- Division of Medicinal Chemistry, Department of BioMolecular Sciences, University of Mississippi, Mississippi, 38677, USA
| | - Xiaojuan Wang
- School of Pharmacy, Lanzhou University, Lanzhou, 730000, Gansu, PR China
| | - Guodong Yao
- School of Traditional Chinese Materia Medica, Shenyang Pharmaceutical University, Shenyang, 110016, PR China
| | - Wanchun Chu
- School of Traditional Chinese Materia Medica, Shenyang Pharmaceutical University, Shenyang, 110016, PR China
| | - Xin Chen
- School of Traditional Chinese Materia Medica, Shenyang Pharmaceutical University, Shenyang, 110016, PR China
| | - Shaojiang Song
- School of Traditional Chinese Materia Medica, Shenyang Pharmaceutical University, Shenyang, 110016, PR China
| | - Mark T Hamann
- College of Pharmacy & Medicine, Medical University of South Carolina, Charleston, SC, 29425-5700, USA.
| | - Lingzhi Li
- School of Traditional Chinese Materia Medica, Shenyang Pharmaceutical University, Shenyang, 110016, PR China.
| |
Collapse
|
2
|
Abstract
The FGF receptors (FGFRs) belong to a family of receptor tyrosine kinases. Abundant evidence shows that FGFRs are closely related to tumor cell invasion and angiogenesis. Hence, targeted modulation of FGFRs has become an effective strategy for cancer treatment. Recently, the development of small-molecule inhibitors targeting FGFRs has been extensively studied, and three inhibitors have been approved for marketing. Based on the clinical problems with the current inhibitors, there is a need to develop novel inhibitors and technologies to address the pitfalls. This review summarizes recent advances in small-molecule inhibitors targeting FGFRs, focusing on structure-activity relationships. Moreover, recent progress of novel technologies are summarized to provide a reference for promoting the application of drugs targeting FGFRs in tumor therapy.
Collapse
|
3
|
Patra P. A short review on the synthesis of pyrrolo[3,4- c]coumarins an isolamellarin-B scaffolds. SYNTHETIC COMMUN 2022. [DOI: 10.1080/00397911.2022.2119413] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/14/2022]
Affiliation(s)
- Prasanta Patra
- Department of Chemistry, Jhargram Raj College, Jhargram, India
| |
Collapse
|
4
|
Sosič I, Gobec M, Steinebach C, Schlesinger M, Bendas G, Gütschow M. Another structural correction for 1-oxo-1H-phenalene-2,3-dicarbonitriles: Synthesis of a potent BCL-2 inhibiting 7-phenoxy derivative. Arch Pharm (Weinheim) 2021; 354:e2100151. [PMID: 34173255 DOI: 10.1002/ardp.202100151] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/19/2021] [Revised: 06/03/2021] [Accepted: 06/07/2021] [Indexed: 11/12/2022]
Abstract
Aromatic scaffolds are an important part of biologically active compounds and molecular probes used to study biochemical pathways and the involved targeted proteins of interest. 1-Oxo-1H-phenalene-2,3-dicarbonitrile-based compounds have been described as inhibitors of the BCL-2 family of proteins, and this core structure represents numerous possibilities for modifications that could lead to improved inhibitory potencies. Many studies demonstrated intriguing characteristics of these compounds in terms of reactivity and, interestingly, some contradictory literature reports appeared about reaction outcomes to synthesize them. Here, we initially provide a condensed overview of transformations performed on the phenalene scaffold, followed by the resynthesis of a 6-phenoxy-substituted derivative. We show that the initial determination of this particular structure was wrong and provide two-dimensional nuclear magnetic resonance (NMR) evidence to assign the structure properly. When preparing new derivatives using the same synthetic route, we observed 6- and 7-substituted regioisomers. After confirming their structures by NMR experiments, the ability of these compounds to inhibit BCL-2 was evaluated. The most potent 1-oxo-1H-phenalene-2,3-dicarbonitrile derivatives inhibited BCL-2 in the nanomolar range and showed double-digit micromolar cytotoxicity against four different cancer cell lines.
Collapse
Affiliation(s)
- Izidor Sosič
- Faculty of Pharmacy, University of Ljubljana, Ljubljana, Slovenia
| | - Martina Gobec
- Faculty of Pharmacy, University of Ljubljana, Ljubljana, Slovenia
| | - Christian Steinebach
- Department of Pharmaceutical & Medicinal Chemistry, Pharmaceutical Institute, University of Bonn, Bonn, Germany
| | - Martin Schlesinger
- Department of Pharmaceutical & Cell Biological Chemistry, Pharmaceutical Institute, University of Bonn, Bonn, Germany
| | - Gerd Bendas
- Department of Pharmaceutical & Cell Biological Chemistry, Pharmaceutical Institute, University of Bonn, Bonn, Germany
| | - Michael Gütschow
- Department of Pharmaceutical & Medicinal Chemistry, Pharmaceutical Institute, University of Bonn, Bonn, Germany
| |
Collapse
|
5
|
Samanta K, Patra P, Kar GK, Dinda SK, Mahanty DS. Diverse synthesis of pyrrolo/indolo[3,2- c]coumarins as isolamellarin-A scaffolds: a brief update. NEW J CHEM 2021. [DOI: 10.1039/d0nj06267g] [Citation(s) in RCA: 6] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/29/2022]
Abstract
This review presents a different synthetic approach of pyrrolo/indolo[3,2-c]coumarins via classical reactions including metal-catalyzed and green reaction protocols.
Collapse
Affiliation(s)
- Khokan Samanta
- Department of Chemistry
- Haldia Government College
- Purba Medinipur
- India
| | - Prasanta Patra
- Department of Chemistry
- Jhargram Raj College
- Jhargram 721507
- India
| | | | - Shaishab Kumar Dinda
- Department of Chemistry
- Government General Degree College Datan II
- Paschim Medinipur
- India
| | | |
Collapse
|
6
|
Jain R, Grover A. Maslinic acid differentially exploits the MAPK pathway in estrogen-positive and triple-negative breast cancer to induce mitochondrion-mediated, caspase-independent apoptosis. Apoptosis 2020; 25:817-834. [PMID: 32940876 DOI: 10.1007/s10495-020-01636-y] [Citation(s) in RCA: 8] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 09/03/2020] [Indexed: 12/14/2022]
Abstract
Breast cancer accounts for 1.4 million new cases every year. Triple-negative breast cancer (TNBC) is one the leading cause of mortality in developing countries and is associated with early age onset (under 40 years old). Chemotherapy has a poor success rate in patients with TNBC as compared to other types of breast cancers. It is due to the lack of expression of three validated molecular markers for breast cancer, the estrogen and progesterone receptors, and the amplification of HER-2/Neu. Therefore, a clear need exists for a greater understanding of TNBC at all levels and for the development of better therapies. We have studied the anti-tumor effects of a potential drug, maslinic acid, which can be extracted from olive oil industry waste. This natural product showed inhibitory effect at concentrations ranging from 30 to 50 µM within 24 h. It exhibited divergent effects in cell cycle progression for the MCF7 (estrogen positive) cell line when compared with TNBCs like MDA-MB-231 and MDA-MB-468. Also, maslinic acid treatment altered the mitochondrial membrane electrochemical potential and the reactive oxygen species (ROS) levels to cause a caspase-independent programmed cell death. In silico approaches and immunoblotting suggested the involvement of the MAPK pathway explaining the variability in cell cycle progression along with the apoptotic cell death caused by maslinic acid.
Collapse
Affiliation(s)
- R Jain
- School of Biotechnology, Jawaharlal Nehru University, New Delhi, 110067, India
| | - A Grover
- School of Biotechnology, Jawaharlal Nehru University, New Delhi, 110067, India.
| |
Collapse
|
7
|
Synthesis and anticancer activity of novel 3,6-disubstituted 1,2,4-triazolo-[3,4-b]-1,3,4-thiadiazole derivatives. ARAB J CHEM 2019. [DOI: 10.1016/j.arabjc.2016.09.015] [Citation(s) in RCA: 19] [Impact Index Per Article: 3.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/04/2023] Open
|
8
|
Volynets G, Lukashov S, Borysenko I, Gryshchenko A, Starosyla S, Bdzhola V, Ruban T, Iatsyshyna A, Lukash L, Bilokin Y, Yarmoluk S. Identification of protein kinase fibroblast growth factor receptor 1 (FGFR1) inhibitors among the derivatives of 5-(5,6-dimethoxybenzimidazol-1-yl)-3-hydroxythiophene-2-carboxylic acid. MONATSHEFTE FUR CHEMIE 2019. [DOI: 10.1007/s00706-019-02493-5] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 12/14/2022]
|
9
|
Chen Z, Tong LJ, Tang BY, Liu HY, Wang X, Zhang T, Cao XW, Chen Y, Li HL, Qian XH, Xu YF, Xie H, Ding J. C11, a novel fibroblast growth factor receptor 1 (FGFR1) inhibitor, suppresses breast cancer metastasis and angiogenesis. Acta Pharmacol Sin 2019; 40:823-832. [PMID: 30487650 DOI: 10.1038/s41401-018-0191-7] [Citation(s) in RCA: 12] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/21/2018] [Accepted: 10/22/2018] [Indexed: 11/09/2022] Open
Abstract
The fibroblast growth factor receptors (FGFRs) are increasingly considered attractive targets for therapeutic cancer intervention due to their roles in tumor metastasis and angiogenesis. Here, we identified a new selective FGFR inhibitor, C11, and assessed its antitumor activities. C11 was a selective FGFR1 inhibitor with an IC50 of 19 nM among a panel of 20 tyrosine kinases. C11 inhibited cell proliferation in various tumors, particularly bladder cancer and breast cancer. C11 also inhibited breast cancer MDA-MB-231 cell migration and invasion via suppression of FGFR1 phosphorylation and its downstream signaling pathway. Suppression of matrix metalloproteinases 2/9 (MMP2/9) was associated with the anti-motility activity of C11. Furthermore, the anti-angiogenesis activity of C11 was verified in endothelial cells and chicken chorioallantoic membranes (CAMs). C11 inhibited the migration and tube formation of HMEC-1 endothelial cells and inhibited angiogenesis in a CAM assay. In sum, C11 is a novel selective FGFR1 inhibitor that exhibits potent activity against breast cancer metastasis and angiogenesis.
Collapse
|
10
|
Chen Z, Xu Y, Qian X. Naphthalimides and analogues as antitumor agents: A review on molecular design, bioactivity and mechanism of action. CHINESE CHEM LETT 2018. [DOI: 10.1016/j.cclet.2018.09.020] [Citation(s) in RCA: 26] [Impact Index Per Article: 4.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/08/2023]
|
11
|
Bavadi M, Niknam K, Shahraki O. Novel pyrrole derivatives bearing sulfonamide groups: Synthesis in vitro cytotoxicity evaluation, molecular docking and DFT study. J Mol Struct 2017. [DOI: 10.1016/j.molstruc.2017.06.003] [Citation(s) in RCA: 17] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/19/2022]
|
12
|
Chaudhari R, Tan Z, Huang B, Zhang S. Computational polypharmacology: a new paradigm for drug discovery. Expert Opin Drug Discov 2017; 12:279-291. [PMID: 28067061 PMCID: PMC7241838 DOI: 10.1080/17460441.2017.1280024] [Citation(s) in RCA: 62] [Impact Index Per Article: 8.9] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/01/2023]
Abstract
INTRODUCTION Over the past couple of years, the cost of drug development has sharply increased along with the high rate of clinical trial failures. Such increase in expenses is partially due to the inability of the "one drug - one target" approach to predict drug side effects and toxicities. To tackle this issue, an alternative approach, known as polypharmacology, is being adopted to study small molecule interactions with multiple targets. Apart from developing more potent and effective drugs, this approach allows for studies of off-target activities and the facilitation of drug repositioning. Although exhaustive polypharmacology studies in-vitro or in-vivo are not practical, computational methods of predicting unknown targets or side effects are being developed. Areas covered: This article describes various computational approaches that have been developed to study polypharmacology profiles of small molecules. It also provides a brief description of the algorithms used in these state-of-the-art methods. Expert opinion: Recent success in computational prediction of multi-targeting drugs has established polypharmacology as a promising alternative approach to tackle some of the daunting complications in drug discovery. This will not only help discover more effective agents, but also present tremendous opportunities to study novel target pharmacology and facilitate drug repositioning efforts in the pharmaceutical industry.
Collapse
Affiliation(s)
- Rajan Chaudhari
- Integrated Molecular Discovery Laboratory, Department of Experimental Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX 77030
| | - Zhi Tan
- Integrated Molecular Discovery Laboratory, Department of Experimental Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX 77030
- The University of Texas Graduate School of Biomedical Sciences, Houston, TX 77030
| | - Beibei Huang
- Integrated Molecular Discovery Laboratory, Department of Experimental Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX 77030
| | - Shuxing Zhang
- Integrated Molecular Discovery Laboratory, Department of Experimental Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX 77030
- The University of Texas Graduate School of Biomedical Sciences, Houston, TX 77030
| |
Collapse
|
13
|
Application of computational methods for anticancer drug discovery, design, and optimization. BOLETIN MEDICO DEL HOSPITAL INFANTIL DE MEXICO 2016; 73:411-423. [PMID: 29421286 PMCID: PMC7110968 DOI: 10.1016/j.bmhimx.2016.10.006] [Citation(s) in RCA: 28] [Impact Index Per Article: 3.5] [Reference Citation Analysis] [Abstract] [Key Words] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/02/2016] [Accepted: 10/17/2016] [Indexed: 02/05/2023] Open
Abstract
Developing a novel drug is a complex, risky, expensive and time-consuming venture. It is estimated that the conventional drug discovery process ending with a new medicine ready for the market can take up to 15 years and more than a billion USD. Fortunately, this scenario has recently changed with the arrival of new approaches. Many novel technologies and methodologies have been developed to increase the efficiency of the drug discovery process, and computational methodologies have become a crucial component of many drug discovery programs. From hit identification to lead optimization, techniques such as ligand- or structure-based virtual screening are widely used in many discovery efforts. It is the case for designing potential anticancer drugs and drug candidates, where these computational approaches have had a major impact over the years and have provided fruitful insights into the field of cancer. In this paper, we review the concept of rational design presenting some of the most representative examples of molecules identified by means of it. Key principles are illustrated through case studies including specifically successful achievements in the field of anticancer drug design to demonstrate that research advances, with the aid of in silico drug design, have the potential to create novel anticancer drugs.
Collapse
|
14
|
Prada-Gracia D, Huerta-Yépez S, Moreno-Vargas LM. Application of computational methods for anticancer drug discovery, design, and optimization. ACTA ACUST UNITED AC 2016. [PMCID: PMC7154613 DOI: 10.1016/j.bmhime.2017.11.040] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/15/2022]
Abstract
Developing a novel drug is a complex, risky, expensive and time-consuming venture. It is estimated that the conventional drug discovery process ending with a new medicine ready for the market can take up to 15 years and more than a billion USD. Fortunately, this scenario has recently changed with the arrival of new approaches. Many novel technologies and methodologies have been developed to increase the efficiency of the drug discovery process, and computational methodologies have become a crucial component of many drug discovery programs. From hit identification to lead optimization, techniques such as ligand- or structure-based virtual screening are widely used in many discovery efforts. It is the case for designing potential anticancer drugs and drug candidates, where these computational approaches have had a major impact over the years and have provided fruitful insights into the field of cancer. In this paper, we review the concept of rational design presenting some of the most representative examples of molecules identified by means of it. Key principles are illustrated through case studies including specifically successful achievements in the field of anticancer drug design to demonstrate that research advances, with the aid of in silico drug design, have the potential to create novel anticancer drugs.
Collapse
Affiliation(s)
- Diego Prada-Gracia
- Department of Pharmacological Sciences, Icahn Medical Institute Building, Icahn School of Medicine at Mount Sinai, New York, USA
| | - Sara Huerta-Yépez
- Unidad de Investigación en Enfermedades Oncológicas, Hospital Infantil de México Federico Gómez, Mexico City, Mexico
| | - Liliana M. Moreno-Vargas
- Unidad de Investigación en Enfermedades Oncológicas, Hospital Infantil de México Federico Gómez, Mexico City, Mexico
- Corresponding author.
| |
Collapse
|
15
|
Kim JH, Kwak Y, Song C, Roh EJ, Oh CH, Lee SH, Sim T, Choi JH, Yoo KH. Synthesis of novel arylaminoquinazolinylurea derivatives and their antiproliferative activities against bladder cancer cell line. Bioorg Med Chem Lett 2016; 26:5082-5086. [PMID: 27599742 DOI: 10.1016/j.bmcl.2016.08.076] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/23/2016] [Revised: 08/18/2016] [Accepted: 08/24/2016] [Indexed: 10/21/2022]
Abstract
A novel series of arylurea and arylamide derivatives 1a-z, 2a-d having aminoquinazoline scaffold was designed and synthesized. Their in vitro antiproliferative activities against RT112 bladder cancer cell line and inhibitory activities against FGFR3 kinase were tested. Most compounds showed good antiproliferative activities against RT112 bladder cancer cell line, and arylurea compounds 1a-z were more potent than arylamide compounds 2a-d. Among them, eight compounds 1a, 1d-g, 1l, 1y, and 1z showed potent activities with GI50 values below submicromolar range. Especially, arylurea compounds 1d and 1g possessing 2,3-dimethyl and 3,4-dimethyl moieties exhibited superior or similar antiproliferative activity (GI50=8.8nM and 30.2nM, respectively) to AZD4547 (GI50=29.2nM) as a reference standard.
Collapse
Affiliation(s)
- Jung Hun Kim
- Chemical Kinomics Research Center, Korea Institute of Science and Technology, PO Box 131, Cheongryang, Seoul 130-650, Republic of Korea; Department of Chemistry, Hanyang University, Seoul 133-791, Republic of Korea
| | - Yeonui Kwak
- Chemical Kinomics Research Center, Korea Institute of Science and Technology, PO Box 131, Cheongryang, Seoul 130-650, Republic of Korea
| | - Chiman Song
- Chemical Kinomics Research Center, Korea Institute of Science and Technology, PO Box 131, Cheongryang, Seoul 130-650, Republic of Korea
| | - Eun Joo Roh
- Chemical Kinomics Research Center, Korea Institute of Science and Technology, PO Box 131, Cheongryang, Seoul 130-650, Republic of Korea
| | - Chang-Hyun Oh
- Center for Biomaterials, Korea Institute of Science and Technology, PO Box 131, Cheongryang, Seoul 130-650, Republic of Korea
| | - So Ha Lee
- Chemical Kinomics Research Center, Korea Institute of Science and Technology, PO Box 131, Cheongryang, Seoul 130-650, Republic of Korea
| | - Taebo Sim
- Chemical Kinomics Research Center, Korea Institute of Science and Technology, PO Box 131, Cheongryang, Seoul 130-650, Republic of Korea
| | - Jung Hoon Choi
- Department of Chemistry, Hanyang University, Seoul 133-791, Republic of Korea
| | - Kyung Ho Yoo
- Chemical Kinomics Research Center, Korea Institute of Science and Technology, PO Box 131, Cheongryang, Seoul 130-650, Republic of Korea.
| |
Collapse
|
16
|
The discovery of a novel inhibitor of apoptotic protease activating factor-1 (Apaf-1) for ischemic heart: synthesis, activity and target identification. Sci Rep 2016; 6:29820. [PMID: 27443636 PMCID: PMC4957240 DOI: 10.1038/srep29820] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/21/2015] [Accepted: 06/27/2016] [Indexed: 12/26/2022] Open
Abstract
Apaf-1 is a central component in the apoptosis regulatory network for the treatment of apoptosis related diseases. Excessive Apaf-1 activity induced by myocardial ischemia causes cell injury. No drug targeted to Apaf-1 for treating myocardial ischemia has been reported to the best of our knowledge. In the present work, we synthesized a novel compound, ZYZ-488, which exhibited significant cardioprotective property in significantly increasing the viability of hypoxia-induced H9c2 cardiomyocytes and reducing CK and LDH leakage. Further study suggested the protective activity of ZYZ-488 dependent on its anti-apoptosis effect. This anti-apoptotic effect is most probably related to its disturbing the interaction between Apaf-1 and procaspase-9 as the target fishing and molecular docking indicated. The suppression on the activation of procaspase-9 and procaspase-3 with ZYZ-488 strongly suggested that compound ZYZ-488 could be a novel inhibitor of Apaf-1. In conclusion, ZYZ-488 as a novel small molecule competitive inhibitor of Apaf-1, with the great potential for treating cardiac ischemia.
Collapse
|
17
|
Wang J, Yang F, Zheng L, Ren G, Qi J, Wang Z, Zhao L. Novel selenium-containing acenaphtho[1,2-b]pyrrole derivatives: Synthesis and bioactivity. PHOSPHORUS SULFUR 2016. [DOI: 10.1080/10426507.2015.1072187] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/13/2022]
Affiliation(s)
- Jisong Wang
- Department of Oncology, Laiwu City People's Hospital, Shandong, P. R. China
| | - Fuli Yang
- Department of Oncology, Laiwu City People's Hospital, Shandong, P. R. China
| | - Liang Zheng
- Department of Respiration, Laiwu City People's Hospital, Shandong, P. R. China
| | - Gang Ren
- Department of Oncology, Laiwu City People's Hospital, Shandong, P. R. China
| | - Jiude Qi
- Department of Oncology, Laiwu City People's Hospital, Shandong, P. R. China
| | - Zhijun Wang
- Shandong Wego Pharmaceutical Co. Limited, Shandong, P. R. China
| | - Liwei Zhao
- Shandong Wego Pharmaceutical Co. Limited, Shandong, P. R. China
| |
Collapse
|
18
|
Ye F, Wang Y, Nian S, Wang Y, Chen D, Yu S, Wang S. Synthesis and evaluation of biological and antitumor activities of 5,7-dimethyl- oxazolo[5,4-d]pyrimidine-4,6(5H,7H)-dione derivatives as novel inhibitors of FGFR1. J Enzyme Inhib Med Chem 2015; 30:961-6. [PMID: 25683078 DOI: 10.3109/14756366.2014.1002401] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/14/2022] Open
Abstract
A series of 5,7-dimethyl-oxazolo[5,4-d]pyrimidine-4,6(5H,7H)-dione derivatives, N5a-5l, was designed, synthesized and evaluated for their FGFR1-inhibition ability as well as cytotoxicity against three cancer cell lines (H460, B16F10 and A549) in vitro. Several compounds displayed good-to-excellent potency against these cancer cell lines compared to SU5402. Structure-activity relationship analyses indicated that compounds with a rigid structure and more heteroatoms at the side chain of the parent ring were more effective than those without these substitutions. The compound N5g (37.4% FGFR1 inhibition at 1.0 μM) was identified to have the most potent antitumor activities, with IC50 values of 5.472, 4.260 and 5.837 μM against H460, B16F10 and A549 cell lines, respectively. Together, our results suggest that 5,7-dimethyl-oxazolo[5,4-d]pyrimidine-4,6(5H,7H)-dione derivatives may serve as potential agents for the treatment of FGFR1-mediated cancers.
Collapse
Affiliation(s)
- Faqing Ye
- a School of Pharmacy, Health Science Center Xi'an Jiaotong University , Xi'an , China and.,b School of Pharmaceutical Sciences, Wenzhou Medical University , Wenzhou , China
| | - Yuewu Wang
- b School of Pharmaceutical Sciences, Wenzhou Medical University , Wenzhou , China
| | - Siyun Nian
- b School of Pharmaceutical Sciences, Wenzhou Medical University , Wenzhou , China
| | - Yu Wang
- b School of Pharmaceutical Sciences, Wenzhou Medical University , Wenzhou , China
| | - Di Chen
- b School of Pharmaceutical Sciences, Wenzhou Medical University , Wenzhou , China
| | - Shufang Yu
- b School of Pharmaceutical Sciences, Wenzhou Medical University , Wenzhou , China
| | - Sicen Wang
- a School of Pharmacy, Health Science Center Xi'an Jiaotong University , Xi'an , China and
| |
Collapse
|
19
|
Xiao Y, Liu F, Chen Z, Zhu W, Xu Y, Qian X. Discovery of a novel family of polycyclic aromatic molecules with unique reactivity and members valuable for fluorescent sensing and medicinal chemistry. Chem Commun (Camb) 2015; 51:6480-8. [DOI: 10.1039/c4cc09846c] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/21/2022]
Abstract
We review major achievements in the study of derivatives of 1-oxo-1H-phenalene-2,3-dicarbonitrile.
Collapse
Affiliation(s)
- Yi Xiao
- State Key Laboratory of Fine Chemicals
- Dalian University of Technology
- Dalian 116024
- China
| | - Fengyu Liu
- State Key Laboratory of Fine Chemicals
- Dalian University of Technology
- Dalian 116024
- China
| | - Zhuo Chen
- Shanghai Key Laboratory of Chemical Biology
- School of Pharmacy
- East China University of Science and Technology
- Shanghai 200237
- China
| | - Weipin Zhu
- Shanghai Key Laboratory of Chemical Biology
- School of Pharmacy
- East China University of Science and Technology
- Shanghai 200237
- China
| | - Yufang Xu
- Shanghai Key Laboratory of Chemical Biology
- School of Pharmacy
- East China University of Science and Technology
- Shanghai 200237
- China
| | - Xuhong Qian
- Shanghai Key Laboratory of Chemical Biology
- School of Pharmacy
- East China University of Science and Technology
- Shanghai 200237
- China
| |
Collapse
|
20
|
Roy D, Sarkar S, Laha RM, Pramanik N, Maiti DK. Ni(0)–Cu(i): a powerful combo catalyst for simultaneous coupling and cleavage of the C–N bond with cyclization to valuable amide-based pyrroles and 4-pyridones. RSC Adv 2015. [DOI: 10.1039/c5ra12115a] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/16/2022] Open
Abstract
We demonstrate unprecedented Ni(0)–Cu(i) combo catalysis for sequential bond activated domino N–C/C–C coupled annulation with N–C bond cleavage to afford valuable amide-based polysubstituted pyrroles and 4-pyridones selectively from β-ketoanilides.
Collapse
Affiliation(s)
- Dipanwita Roy
- Department of Chemistry
- University of Calcutta
- Kolkata-700009
- India
| | - Satinath Sarkar
- Department of Chemistry
- University of Calcutta
- Kolkata-700009
- India
| | - Radha M. Laha
- Department of Chemistry
- University of Calcutta
- Kolkata-700009
- India
| | | | - Dilip K. Maiti
- Department of Chemistry
- University of Calcutta
- Kolkata-700009
- India
| |
Collapse
|
21
|
Chen SJ, Ren JL. Identification of a potential anticancer target of danshensu by inverse docking. Asian Pac J Cancer Prev 2014; 15:111-6. [PMID: 24528010 DOI: 10.7314/apjcp.2014.15.1.111] [Citation(s) in RCA: 19] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/10/2022] Open
Abstract
OBJECTIVE To study potential targets of Danshensu via dual inverse docking. METHOD PharmMapper and idTarget servers were used as tools, and the results were checked with the molecular docking program autodock vina in PyRx 0.8. RESULT The disease-related target HRas was rated top, with a pharmacophore model matching well the molecular features of Danshensu. In addition, docking results indicated that the complex was also matched in terms of structure, H-bonds, and hydrophobicity. CONCLUSION Dual inverse docking indicates that HRas may be a potential anticancer target of Danshensu. This approach can provide useful information for studying pharmacological effects of agents of interest.
Collapse
Affiliation(s)
- Shao-Jun Chen
- Department of Traditional Chinese Medicine, Zhejiang Pharmaceutical College, Ningbo, China E-mail :
| | | |
Collapse
|
22
|
Lenk R, Tessier A, Lefranc P, Silvestre V, Planchat A, Blot V, Dubreuil D, Lebreton J. 1-Oxo-1H-phenalene-2,3-dicarbonitrile Heteroaromatic Scaffold: Revised Structure and Mechanistic Studies. J Org Chem 2014; 79:9754-61. [DOI: 10.1021/jo5016932] [Citation(s) in RCA: 13] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
Affiliation(s)
- Romaric Lenk
- Université de Nantes, CNRS, CEISAM, UMR CNRS 6230, Faculté des Sciences
et des Techniques, 2 rue de la Houssinière, BP 92208, 44322 Nantes Cedex 3, France
| | - Arnaud Tessier
- Université de Nantes, CNRS, CEISAM, UMR CNRS 6230, Faculté des Sciences
et des Techniques, 2 rue de la Houssinière, BP 92208, 44322 Nantes Cedex 3, France
| | - Pierre Lefranc
- Université de Nantes, CNRS, CEISAM, UMR CNRS 6230, Faculté des Sciences
et des Techniques, 2 rue de la Houssinière, BP 92208, 44322 Nantes Cedex 3, France
| | - Virginie Silvestre
- Université de Nantes, CNRS, CEISAM, UMR CNRS 6230, Faculté des Sciences
et des Techniques, 2 rue de la Houssinière, BP 92208, 44322 Nantes Cedex 3, France
| | - Aurélien Planchat
- Université de Nantes, CNRS, CEISAM, UMR CNRS 6230, Faculté des Sciences
et des Techniques, 2 rue de la Houssinière, BP 92208, 44322 Nantes Cedex 3, France
| | - Virginie Blot
- Université de Nantes, CNRS, CEISAM, UMR CNRS 6230, Faculté des Sciences
et des Techniques, 2 rue de la Houssinière, BP 92208, 44322 Nantes Cedex 3, France
| | - Didier Dubreuil
- Université de Nantes, CNRS, CEISAM, UMR CNRS 6230, Faculté des Sciences
et des Techniques, 2 rue de la Houssinière, BP 92208, 44322 Nantes Cedex 3, France
| | - Jacques Lebreton
- Université de Nantes, CNRS, CEISAM, UMR CNRS 6230, Faculté des Sciences
et des Techniques, 2 rue de la Houssinière, BP 92208, 44322 Nantes Cedex 3, France
| |
Collapse
|
23
|
Wang X, Chen H, Yang F, Gong J, Li S, Pei J, Liu X, Jiang H, Lai L, Li H. iDrug: a web-accessible and interactive drug discovery and design platform. J Cheminform 2014; 6:28. [PMID: 24955134 PMCID: PMC4046018 DOI: 10.1186/1758-2946-6-28] [Citation(s) in RCA: 28] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/20/2014] [Accepted: 05/12/2014] [Indexed: 01/06/2023] Open
Abstract
BACKGROUND The progress in computer-aided drug design (CADD) approaches over the past decades accelerated the early-stage pharmaceutical research. Many powerful standalone tools for CADD have been developed in academia. As programs are developed by various research groups, a consistent user-friendly online graphical working environment, combining computational techniques such as pharmacophore mapping, similarity calculation, scoring, and target identification is needed. RESULTS We presented a versatile, user-friendly, and efficient online tool for computer-aided drug design based on pharmacophore and 3D molecular similarity searching. The web interface enables binding sites detection, virtual screening hits identification, and drug targets prediction in an interactive manner through a seamless interface to all adapted packages (e.g., Cavity, PocketV.2, PharmMapper, SHAFTS). Several commercially available compound databases for hit identification and a well-annotated pharmacophore database for drug targets prediction were integrated in iDrug as well. The web interface provides tools for real-time molecular building/editing, converting, displaying, and analyzing. All the customized configurations of the functional modules can be accessed through featured session files provided, which can be saved to the local disk and uploaded to resume or update the history work. CONCLUSIONS iDrug is easy to use, and provides a novel, fast and reliable tool for conducting drug design experiments. By using iDrug, various molecular design processing tasks can be submitted and visualized simply in one browser without installing locally any standalone modeling softwares. iDrug is accessible free of charge at http://lilab.ecust.edu.cn/idrug.
Collapse
Affiliation(s)
- Xia Wang
- Shanghai Key Laboratory of New Drug Design, State Key Laboratory of Bioreactor Engineering, School of Pharmacy, East China University of Science and Technology, Shanghai 200237, China
| | - Haipeng Chen
- School of Information Science and Engineering, East China University of Science and Technology, Shanghai 200237, China
| | - Feng Yang
- School of Information Science and Engineering, East China University of Science and Technology, Shanghai 200237, China
| | - Jiayu Gong
- School of Information Science and Engineering, East China University of Science and Technology, Shanghai 200237, China
| | - Shiliang Li
- Shanghai Key Laboratory of New Drug Design, State Key Laboratory of Bioreactor Engineering, School of Pharmacy, East China University of Science and Technology, Shanghai 200237, China
| | - Jianfeng Pei
- BNLMS, Center for Quantitative Biology, State Key Laboratory for Structural Chemistry of Unstable and Stable Species, College of Chemistry and Molecular Engineering, Peking University, Beijing 100871, China
| | - Xiaofeng Liu
- Shanghai Key Laboratory of New Drug Design, State Key Laboratory of Bioreactor Engineering, School of Pharmacy, East China University of Science and Technology, Shanghai 200237, China
| | - Hualiang Jiang
- Shanghai Key Laboratory of New Drug Design, State Key Laboratory of Bioreactor Engineering, School of Pharmacy, East China University of Science and Technology, Shanghai 200237, China
| | - Luhua Lai
- BNLMS, Center for Quantitative Biology, State Key Laboratory for Structural Chemistry of Unstable and Stable Species, College of Chemistry and Molecular Engineering, Peking University, Beijing 100871, China
| | - Honglin Li
- Shanghai Key Laboratory of New Drug Design, State Key Laboratory of Bioreactor Engineering, School of Pharmacy, East China University of Science and Technology, Shanghai 200237, China ; School of Information Science and Engineering, East China University of Science and Technology, Shanghai 200237, China
| |
Collapse
|
24
|
Discovery and identification of new non-ATP competitive FGFR1 inhibitors with therapeutic potential on non-small-cell lung cancer. Cancer Lett 2014; 344:82-89. [DOI: 10.1016/j.canlet.2013.10.016] [Citation(s) in RCA: 28] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/30/2013] [Revised: 09/26/2013] [Accepted: 10/18/2013] [Indexed: 11/23/2022]
|
25
|
Zheng M, Liu X, Xu Y, Li H, Luo C, Jiang H. Computational methods for drug design and discovery: focus on China. Trends Pharmacol Sci 2013; 34:549-59. [PMID: 24035675 PMCID: PMC7126378 DOI: 10.1016/j.tips.2013.08.004] [Citation(s) in RCA: 47] [Impact Index Per Article: 4.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/02/2013] [Revised: 08/07/2013] [Accepted: 08/13/2013] [Indexed: 01/09/2023]
Abstract
The leading computational techniques for drug design and discovery are reviewed. Successful applications of computational techniques are provided. A novel drug–target binding kinetics calculation approach is introduced.
In the past decades, China's computational drug design and discovery research has experienced fast development through various novel methodologies. Application of these methods spans a wide range, from drug target identification to hit discovery and lead optimization. In this review, we firstly provide an overview of China's status in this field and briefly analyze the possible reasons for this rapid advancement. The methodology development is then outlined. For each selected method, a short background precedes an assessment of the method with respect to the needs of drug discovery, and, in particular, work from China is highlighted. Furthermore, several successful applications of these methods are illustrated. Finally, we conclude with a discussion of current major challenges and future directions of the field.
Collapse
Affiliation(s)
- Mingyue Zheng
- Drug Discovery and Design Center, State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, 555 Zuchongzhi Road, Shanghai 201203, China
| | | | | | | | | | | |
Collapse
|
26
|
Current strategies for inhibiting FGFR activities in clinical applications: opportunities, challenges and toxicological considerations. Drug Discov Today 2013; 19:51-62. [PMID: 23932951 DOI: 10.1016/j.drudis.2013.07.021] [Citation(s) in RCA: 53] [Impact Index Per Article: 4.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/31/2013] [Revised: 07/23/2013] [Accepted: 07/30/2013] [Indexed: 01/23/2023]
Abstract
Aberrations in fibroblast growth factor receptor (FGFR) signaling are instrumental to the pathophysiology of several malignancies and disorders. Hence, FGFR inhibitors are explored in therapeutics with early candidates developed as competitors for the ATP-binding pocket in the kinase domain. More recent programs yielded compounds of diverse scaffolds with alternative binding modes. Concurrently, monoclonal antibodies and peptide-based agents provide independent options for clinical development. Notwithstanding this rapid progress, we contemplate the toxicological impact of FGFR inhibition based on the defined role of FGFR family members in physiology and homeostasis. The high homology among FGFR1-4 and also with other kinase subfamilies creates an additional challenge in developing selective inhibitors. It orchestrates an ongoing conundrum of moderating a balance between synergism through multitargeting kinase inhibition and minimizing off-target toxicities.
Collapse
|
27
|
Dhara D, Gayen KS, Khamarui S, Pandit P, Ghosh S, Maiti DK. CeCl3·7H2O Catalyzed C–C and C–N Bond-Forming Cascade Cyclization with Subsequent Side-Chain Functionalization and Rearrangement: A Domino Approach to Pentasubstituted Pyrrole Analogues. J Org Chem 2012; 77:10441-9. [DOI: 10.1021/jo301796r] [Citation(s) in RCA: 38] [Impact Index Per Article: 3.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/11/2022]
Affiliation(s)
- Dipankar Dhara
- Department
of Chemistry, University of Calcutta, University College of Science, 92, A. P. C.
Road, Kolkata-700009, India
| | - Krishnanka S. Gayen
- Department
of Chemistry, University of Calcutta, University College of Science, 92, A. P. C.
Road, Kolkata-700009, India
| | - Saikat Khamarui
- Department
of Chemistry, University of Calcutta, University College of Science, 92, A. P. C.
Road, Kolkata-700009, India
| | - Palash Pandit
- Department
of Chemistry, University of Calcutta, University College of Science, 92, A. P. C.
Road, Kolkata-700009, India
| | - Sukla Ghosh
- Department
of Chemistry, University of Calcutta, University College of Science, 92, A. P. C.
Road, Kolkata-700009, India
| | - Dilip K. Maiti
- Department
of Chemistry, University of Calcutta, University College of Science, 92, A. P. C.
Road, Kolkata-700009, India
| |
Collapse
|
28
|
Liang G, Liu Z, Wu J, Cai Y, Li X. Anticancer molecules targeting fibroblast growth factor receptors. Trends Pharmacol Sci 2012; 33:531-41. [PMID: 22884522 DOI: 10.1016/j.tips.2012.07.001] [Citation(s) in RCA: 92] [Impact Index Per Article: 7.7] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/25/2012] [Revised: 06/28/2012] [Accepted: 07/10/2012] [Indexed: 01/25/2023]
Abstract
The fibroblast growth factor receptor (FGFR) family includes four highly conserved receptor tyrosine kinases: FGFR1-4. Upon ligand binding, FGFRs activate an array of downstream signaling pathways, such as the mitogen activated protein kinase (MAPK) and the phosphoinositide-3-kinase (PI3K)/Akt pathways. These FGFR cascades play crucial roles in tumor cell proliferation, angiogenesis, migration, and survival. The combination of knockdown studies and pharmaceutical inhibition in preclinical models demonstrates that FGFRs are attractive targets for therapeutic intervention in cancer. Multiple FGFR inhibitors with various structural skeletons have been designed, synthesized, and evaluated. Reviews on FGFRs have recently focused on FGFR signaling, pathophysiology, and functions in cancer or other diseases. In this article, we review recent advances in structure-activity relationships (SAR) of FGFR inhibitors, as well as the FGFR-targeting drug design strategies currently employed in targeting deregulated FGFRs by antibodies and small molecule inhibitors.
Collapse
Affiliation(s)
- Guang Liang
- School of Pharmaceutical Sciences, Wenzhou Medical College, Wenzhou 325035, China.
| | | | | | | | | |
Collapse
|